Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Tirumotecan in Advanced Vaginal and Vulvar Squamous Cell Carcinoma
NCT07804966Phase 2Not yet recruiting
- Sponsor
- Latin American Cooperative Oncology Group
- Start
- Jan 2027
- Primary completion
- Mar 2030
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab tirumotecan in vaginal squamous cell carcinoma (SCCV), vulvar squamous cell carcinoma (VSCC), sponsored by Latin American Cooperative Oncology Group. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
vaginal squamous cell carcinoma (SCCV)vulvar squamous cell carcinoma (VSCC)
Beyond the preview
Go deeper on NCT07804966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07804966.